|Videos|July 18, 2014
Future Immunotherapy Strategies in Cancer
Advertisement
Episodes in this series
For High-Definition, Click
The success of immunotherapies will change the way clinical trials are conducted and reported, suggests Louis M. Weiner, MD. Additionally, the success of these agents will set the bar higher for future therapies.
In this segment, panelists discuss their thoughts on future immunotherapy strategies, including treatment strategies that incorporate chimeric antigen receptor therapies, tumor infiltrating lymphocytes, and vaccines.
View the video, to hear the discussion.
Advertisement
Related to this article
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5